FDA approves treatment for adults with Alzheimer’s disease

Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy

Summary of the Current Status of DNA Vaccination for Alzheimer Disease

Paving the way for anti-Abeta active immunotherapy

PharmaJet Partner, Institute for Molecular Medicine, Launches Clinical Trial for the First in Human Alzheimer’s DNA Vaccine

Alzheimer's vaccine is expected to enter Clinical Phase 1 in the second quarter of the U.S.

DNA vaccine spurs antibodies against a common Parkinson's target in mice

NIH's new Parkinson's disease vaccine will enter human trials

Oh, Where Vaccines Could Take Us

NOVEL PREVENTIVE VACCINE FOR PARKINSON’S DISEASE WOULD MOVE INTO HUMAN TRIALS

Novel Preventive Vaccine for Parkinson's Disease Would Move into Human Trials

Giving Thanks for Scientific Advances and COVID-19 Relief

As gene-editing moves mainstream, a pioneer in the field is testing whether it could prevent Alzheimer's

Alzheimer: passi avanti per lo sviluppo di un vaccino

New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease

Vaccine for Alzheimer’s Could Be on the Horizon

Developing a Vaccine for Alzheimer’s Disease

Nuravax Acquires Rights for MultiTEP Vaccine Platform Tech

Hoag's Pickup Family Neurosciences Institute Selected to Participate in Revolutionary Clinical Trial for the Prevention of Alzheimer's Disease

A novel dementia vaccine targeting three B cell epitopes of Pathological α-Synuclein

Gates Biomanufacturing Facility Announces Manufacture of Recombinant Protein - Alzheimer's Disease Vaccine for Institute for Molecular Medicine's Clinical Trials

Institute for Molecular Medicine Receives $12 Million NIH Grant to Fund Clinical Trials of AV-1959, First Preventive Vaccine for Alzheimer's Disease

Novel Preventive Vaccine for Parkinson's Disease Would Move into Human Trials

The Institute for Molecular Medicine Exclusively Licenses MultiTEP, a Universal Vaccine Platform Technology, to New Biotechnology Company Nuravax

The Institute for Molecular Medicine has Received a Total $7.7M From NIH to Develop a First-of-its-Kind Vaccine Targeting Both Hallmarks of Alzheimer's Disease